---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-107329"
form_type: "8-K"
ticker: "TTRX"
cik: "0002023016"
company_name: "Turn Therapeutics Inc."
filed_at: "2026-10-06T23:30:52+00:00"
generated_at: "2026-10-12T16:04:21.692345+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Turn Therapeutics files Oct 6, 2026 investor presentation; exhibit text shows no financial or pipeline detail

## Summary
- Turn Therapeutics (Nasdaq: TTRX) furnished an updated corporate/investor presentation dated October 6, 2026 under Item 7.01 (Regulation FD).
- Exhibit 99.1 as attached contains only the title line 'Corporate Presentation October 2026' — no revenue, cash, trial, pipeline, or guidance figures are present.
- Filing signed October 6, 2026 by CEO Bradley Burnam; registrant address is 250 N. Westlake Blvd., Westlake Village, California 91362.
- Because no substantive operating or financial data was disclosed, no directional read on the company's results is possible from this filing.

## SEC filing metadata
- accession: 0001213900-26-107329
- form_type: 8-K
- ticker: TTRX
- cik: 0002023016
- company_name: Turn Therapeutics Inc.
- filed_at: 2026-10-06T23:30:52+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2023016/000121390026107329/0001213900-26-107329-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2023016/000121390026107329/ea0307911-8k_turn.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-107329
- JSON: https://secwatch.observer/filing/0001213900-26-107329.json
- Plain text: https://secwatch.observer/filing/0001213900-26-107329.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.